

**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listing of claims in the application. For the Examiner's convenience a complete listing of all claims incorporating the amendments made herein is attached as Appendix A.

**Listing of Claims:**

Claim 1. (Previously Presented): A method for inhibiting the proliferation of mammalian retinal endothelial cells comprising administering a therapeutically effective amount of 3-N-propylxanthine to the mammalian retinal endothelial cells, whereby the proliferation of the mammalian retinal endothelial cells is inhibited.

Claims 2-10 (Canceled)

Claim 11. (Previously Presented): The method of claim 1 wherein the 3-N-propylxanthine is administered in an amount ranging from about 1 microgram/kg to about 50 miligrams/kg.

Claim 12. (Previously Presented): The method of claim 1 wherein the 3-N-propylxanthine is administered in an amount ranging from about 1 microgram/kg to about 10 miligrams/kg.

Claim 13. (Previously Presented): The method of claim 1 wherein the 3-N-propylxanthine is administered by a method selected from the group consisting of orally, nasally, transdermally, by bolus, intravenously, in eye drops, by inhalation, and by using micropumps.

Claim 14. (Previously Presented): The method of claim 1 wherein the 3-N-propylxanthine is administered in eye drops.

Claim 15. (Previously Presented): The method of claim 1 wherein the mammal is a human.

Claims 16-19. (Canceled)